$6.14
4.07% yesterday
Nasdaq, Aug 12, 10:01 pm CET
ISIN
US23954D1090
Symbol
DAWN

Day One Biopharmaceuticals Inc Stock price

$6.14
-0.79 11.40% 1M
-5.99 49.38% 6M
-6.53 51.54% YTD
-7.35 54.48% 1Y
-20.43 76.89% 3Y
+5.09 484.76% 5Y
+5.09 484.76% 10Y
+5.09 484.76% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.24 4.07%
ISIN
US23954D1090
Symbol
DAWN
Industry

Key metrics

Basic
Market capitalization
$604.4m
Enterprise Value
$151.3m
Net debt
positive
Cash
$453.1m
Shares outstanding
102.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.2 | 4.0
EV/Sales
0.8 | 1.0
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
86.3%
Return on Equity
-19.0%
ROCE
-23.9%
ROIC
-208.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$187.6m | $152.7m
EBITDA
$-108.4m | $-168.5m
EBIT
$-111.7m | $-163.1m
Net Income
$-95.0m | $-144.1m
Free Cash Flow
$-69.0m
Growth (TTM | estimate)
Revenue
2,191.1% | 16.4%
EBITDA
62.9% | 21.7%
EBIT
61.8% | 25.0%
Net Income
43.3% | -50.9%
Free Cash Flow
64.5%
Margin (TTM | estimate)
Gross
94.0%
EBITDA
-57.8% | -110.4%
EBIT
-59.6%
Net
-50.6% | -94.3%
Free Cash Flow
-36.8%
More
EPS
$-0.9
FCF per Share
$-0.7
Short interest
15.1%
Employees
169
Rev per Employee
$780.0k
Show more

Is Day One Biopharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Day One Biopharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Day One Biopharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Day One Biopharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
188 188
2,191% 2,191%
100%
- Direct Costs 11 11
1,480% 1,480%
6%
176 176
2,255% 2,255%
94%
- Selling and Administrative Expenses 117 117
20% 20%
62%
- Research and Development Expense 171 171
16% 16%
91%
-108 -108
63% 63%
-58%
- Depreciation and Amortization 3.36 3.36
511% 511%
2%
EBIT (Operating Income) EBIT -112 -112
62% 62%
-60%
Net Profit -95 -95
43% 43%
-51%

In millions USD.

Don't miss a Thing! We will send you all news about Day One Biopharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Day One Biopharmaceuticals Inc Stock News

Positive
Seeking Alpha
5 days ago
OJEMDA's strong efficacy and expanding market share in pLGG, plus a robust cash runway, position Day One for significant upside if FIREFLY-2 succeeds. Current valuation is deeply discounted, reflecting modest launch, small TAM, and confirmatory trial risk, but underappreciates asymmetric reward potential. Early sales growth is solid, though moderating; future catalysts hinge on FIREFLY-2 result...
Neutral
Seeking Alpha
7 days ago
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Charles N. York - COO & CFO Jeremy Bender - CEO, President & Director Joey Perrone - Corporate Participant Lauren Merendino - Chief Commercial Officer Michael Vasconcelles - Corporate Participant Conference Call Participants Alec Warren Stranahan - BofA Securities, Res...
Positive
The Motley Fool
7 days ago
Day One Biopharmaceuticals (DAWN 2.15%), a clinical-stage biopharmaceutical company focused on developing therapies for pediatric cancers and rare tumor types, reported its earnings for Q2 2025 on August 5, 2025. The main headline: robust growth in OJEMDA (tovorafenib) prescription numbers and revenue, although total quarterly revenue (GAAP) of $33.9 million came in slightly below the analyst c...
More Day One Biopharmaceuticals Inc News

Company Profile

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeremy Bender
Employees 169
Founded 2018
Website dayonebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today